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Abstract
Aims To evaluate the dose–response relationship of lixisenatide (AVE0010), a glucagon-like peptide-1 (GLP-1) receptor
agonist, in metformin-treated patients with Type 2 diabetes.
Methods Randomized,double-blind,placebo-controlled,parallel-group,13 weekstudyof542patientswithType 2diabetes
inadequately controlled [glycated haemoglobin (HbA1c) ‡ 7.0 and < 9.0% (‡ 53 and < 75 mmol⁄mol)] on metformin
(‡ 1000 mg⁄day) treated with subcutaneous lixisenatide doses of 5, 10, 20 or 30 lg once daily or twice daily or placebo. The
primary end-point was change in HbA1c from baseline to 13 weeks in the intent-to-treat population.
Results Lixisenatide signiﬁcantly improved mean HbA1c from a baseline of 7.55% (59.0 mmol⁄mol); respective mean
reductions for 5, 10, 20 and 30 lg doses were 0.47, 0.50, 0.69 and 0.76% (5.1, 5.5, 7.5 and 8.3 mmol⁄mol), on once-
daily and 0.65, 0.78, 0.75 and 0.87% (7.1, 8.5, 8.2 and 9.5 mmol⁄mol) on twice-daily administrations vs. 0.18%
(2.0 mmol⁄mol) with placebo (all P < 0.01 vs. placebo). Target HbA1c < 7.0% (53 mmol⁄mol) at study end was
achieved in 68% of patients receiving 20 and 30 lg once-daily lixisenatide vs. 32% receiving placebo (P < 0.0001).
Dose-dependent improvements were observed for fasting, postprandial and average self-monitored seven-point blood
glucose levels. Weight changes ranged from )2.0 to )3.9 kg with lixisenatide vs. )1.9 kg with placebo. The most
frequent adverse event was mild-to-moderate nausea.
Conclusions Lixisenatide signiﬁcantly improved glycaemic control in mildly hyperglycaemic patients with Type 2
diabetes on metformin. Dose–response relationships were seen for once- and twice-daily regimens, with similar efﬁcacy
levels, with a 20 lg once-daily dose of lixisenatide demonstrating the best efﬁcacy-to-tolerability ratio. This new, once-
daily GLP-1 receptor agonist shows promise in the management of Type 2 diabetes to be deﬁned further by ongoing
long-term studies.
Diabet. Med. 27, 1024–1032 (2010)
Keywords glucagon-like peptide-1 receptor agonist, glycaemic control, lixisenatide, Type 2 diabetes
Abbreviations DPP-4, dipeptidyl-peptidase-4; GLP-1, glucagon-like peptide-1; IFCC, International Federation of
Clinical Chemistry and Laboratory Medicine; NGSP, National Glycohemoglobin Standardization Program; QD, once
daily
Introduction
Glycaemic control in Type 2 diabetes mellitus is generally
targeted toward a glycated haemoglobin (HbA1c) level as close
to normal [i.e. < 6.5 or < 7.0% (< 48 or < 53 mmol⁄mol)] as
safely as possible [1,2]. Although a variety of pharmacological
approachesarenowavailable,currentmanagementoftenfailsto
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1024 Diabetic Medicine ª 2010 Diabetes UKachieve glycaemic targets [3]. Analogues of the hormone
glucagon-like peptide-1 (GLP-1) have shown promise as
therapeutic options in Type 2 diabetes. Endogenous GLP-1
enhances insulin secretion and inhibits postprandial glucagon
secretioninaglucose-dependentfashion,slowsgastricemptying,
reduces food intake and promotes weight loss, with all these
effects matched by GLP-1 receptor agonists [4,5]. The
suppression of glucagon by GLP-1 does not occur at
hypoglycaemic glucose levels, and as such exogenous GLP-1
does not impair the physiological mechanisms that counteract
hypoglycaemia [6].
PharmacologicalreplacementwithGLP-1receptoragonistsin
patients with Type 2 diabetes represents anattractivestrategy to
improve metabolic control, particularly as we aim for near-
normalglycaemia,withlessriskofhypoglycaemiaandnoweight
gain or, ideally, weight loss. In addition to improving glycaemic
control, GLP-1 receptor agonists have the potential to preserve
pancreatic islet B cells by enhancing proliferation and inhibiting
apoptosis, based on preclinical studies in animal models and
cultured pancreatic B cells [7–12], but still with no evidence in
human studies.
However, exogenous native GLP-1 is not suitable as a
therapeutic agent because it is rapidly degraded by dipeptidyl
peptidase-4 (DPP-4) and has a half-life of less than 2 min [4].
Thus, DPP-4-resistant GLP-1 receptor agonists with extended
half-liveshavebeendeveloped.Lixisenatide(AVE0010)isanew,
potent, selective and synthetic 44 amino acid exendin-4-like
GLP-1 receptor agonist modiﬁed C-terminally with six Lys
residues and one Pro deleted. In Chinese hamster ovary (CHO)
cellstransfectedwiththehumanGLP-1receptor,lixisenatidehad
abindingafﬁnityapproximately4-foldgreaterthanthatofnative
human GLP-1 (IC50 for lixisenatide = 1.43 nmol⁄lv s .I C 50 for
G L P - 1=5 . 4 8n m o l⁄l) [9,13]. Lixisenatide is being developed
with the aim of improving the management of Type 2 diabetes.
The primary objective of this study was to evaluate thoroughly
thedose–responseeffectoflixisenatideusingonce-ortwice-daily
regimens (5–30 lg once or twice daily) on HbA1c changes over
13 weeks in metformin-treated patients with Type 2 diabetes.
Patients and methods
Study participants
The study population comprised male and female patients aged
30–75 years with Type 2 diabetes mellitus of at least 1 year’s
duration inadequately controlled [HbA1c ‡ 7.0 and < 9.0%
(‡ 53 and < 75 mmol⁄mol)] on stable metformin monotherapy
(‡ 1000 mg⁄day) for at least 3 months prior to screening.
The main exclusion criteria were as follows: history of
gastrointestinal disease with prolonged nausea and vomiting
during the previous 6 months; history of chronic pancreatitis or
stomach⁄gastricsurgery;severecardiovasculareventsduringthe
previous 6 months; or hepatic or renal disease at screening
[serum creatinine ‡ 114.4 lmol⁄l( 1 . 5m g ⁄dl) for males and
‡ 106.8 lmol⁄l( 1 . 4m g⁄dl) for females].
The study was approved by the institutional review boards or
ethics committees and was conducted in accordance with the
DeclarationofHelsinkiandGoodClinicalPracticeguidelines.All
patientsgavewritteninformedconsenttoparticipateinthestudy.
Study design
This13 week,multinational,randomized,parallel-group,placebo-
controlled study was conducted at 133 centres between March
2006 and August 2007. The study drug, added-on to stable
metformin, was double-blind regarding active treatment or
placebo and open-label regarding the treatment volume.
Following a 2 week screening phase, eligible patients entered
into a 2 week, single-blind, placebo run-in period. Eligible
patients were then randomized at visit 4 (week 0) to one of 12
treatment arms (2:2:2:2:2:2:2:2:1:1:1:1): to subcutaneous injec-
tionsoflixisenatidedosesof5,10,20or30 lgadministeredonce
dailywithin1 hbeforebreakfast(withvolume-matchedplacebo
before dinner); to lixisenatide doses of 5, 10, 20 or 30 lg
administered twice daily (10, 20, 40 or 60 lg total daily dose,
respectively) within 1 h before both breakfast and dinner; or to
one of four volume-matched placebo treatments administered
twice daily.
Randomization of subjects, allocation of medication and
management of drug supplies were performed using an
interactive voice response system.
Dose escalation was performed during the ﬁrst 2–4 weeks for
patients randomized to 20 and 30 lg dose levels of the study
medication; the dose was initiated at 10 lg for 1 week and
increasedby5 lg⁄weekuptothetargetdose.Theentrydosageof
metformin remained unchanged throughout the study. All
patients received diet and lifestyle counselling according to the
American Diabetes Association guidelines [1].
Study assessments
The primary efﬁcacy end-point was change in HbA1c from
baselinetostudyendfortheintent-to-treatpopulation.Glycated
haemoglobin was measured at a National Glycohemoglobin
Standardization Program (NGSP) Level 1 certiﬁed central
laboratory, measured with the high-performance liquid chro-
matographymethod.CorrespondingInternationalFederationof
Clinical Chemistry and Laboratory Medicine (IFCC)
standardized values were calculated using the relationship:
IFCC value (in mmol⁄mol) = (NGSP value – 2.152)⁄0.09148
[14,15]. All HbA1c data are given as NGSP standardized values
and IFCC values. The secondary efﬁcacy measures included the
percentageofpatientsachievinganHbA1c<7 . 0o r<6 . 5 %( <5 3
o r<4 8m m o l⁄mol), changes in body weight, fasting plasma
glucose, and 2 h post-prandial plasma glucose after a
standardized breakfast. Self-monitored seven-point blood
glucose measurements were performed at baseline and
week 13. Anti-lixisenatide antibody levels were measured.
Safety and tolerability were assessed by physical examination,
adverse event reporting, blood pressure, heart rate, 12-lead
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Symptomatic hypoglycaemia was deﬁned as symptoms consis-
tent with hypoglycaemia, with an accompanying blood glucose
<3 . 3m m o l⁄l or prompt recovery with carbohydrate.
Statistical analyses
Sample sizes of 50 patients in each active treatment group and
100 patients in the placebo group were calculated to provide a
statistical power of 81% to detect a 0.6% (6.6 mmol⁄mol)
difference in HbA1c between an active treatment and placebo
assuming a standard deviation of 1.2% (13.1 mmol⁄mol).
Statistical signiﬁcance was assumed at the 5% level.
Analyses of the primary efﬁcacy variable (changes in HbA1c
from baseline to end-point) were performed using analysis of
covariance (ANCOVA) model, with treatment and country as
ﬁxed factors and baseline HbA1c as a covariate. Multiple testing
procedure was used for the primary efﬁcacy variable in order to
control Type 1 error for the study and for multiple doses within
each dose regimen (once and twice daily). The step-down trend
test was used from the above ANCOVA model to assess dose–
response relationship within each regimen. The continuous
secondary efﬁcacy variables (change in body weight, fasting
plasma glucose, seven-point self monitored blood glucose and
post-prandial plasma glucose) were analysed using the same
methods used for the primary efﬁcacy variable. Data from
placebo-treatedsubjectswerepooledforstatisticalanalysis.Both
means and least square adjusted means were calculated. The
percentages of patients achieving an HbA1c <7 . 0a n d<6 . 5 %
(< 53 and < 48 mmol⁄mol) were analysed using a Cochran–
Mantel–Haenszel test stratiﬁed by country. Safety and
tolerability data were analysed using descriptive statistics for
all patients who received at least one dose of study medication.
Unless otherwise indicated, all efﬁcacy data were analysed in
the intent-to-treat population (all randomized subjects taking at
least one dose of thestudy medicationand having a baseline and
oneon-treatmentvalueforefﬁcacyvariables);theyarepresented
as means  sem, unless speciﬁed otherwise.
Results
Demographic and baseline characteristics
A total of 542 patients were randomized from 1466 patients
screened. The reasons for screening failure (n = 924) were as
follows: ineligible inclusion criteria (n = 850), patient’s wish
(n = 34) and other (n = 40). Approximately 90% of patients
completed 13 weeks of active treatment, and the percentages
ranged from 83% in the 30 lg lixisenatide once daily group to
96% in the 5 lg lixisenatide once daily and twice daily groups,
compared with 95% in the placebo group (Table 1). Nearly all
patients were at their randomized dose level by study end,
rangingfrom85and89%inthe30 lgoncedailyandtwicedaily
groupsto100%inthe5 lgoncedailyandtwicedailyand10 lg
twice daily groups.
Demographic and baseline characteristics were well matched,
and there were no clinically relevant differences between groups
(Table 1).
Efﬁcacy
There were signiﬁcantly greater improvements in the primary
efﬁcacyend-pointofHbA1cchangefromameanoverallbaseline
of 7.55% (59.0 mmol⁄mol) in all the lixisenatide groups
(P < 0.01 vs. placebo), with reductions ranging from 0.47 to
0.87% (from 5.1 to 9.5 mmol⁄mol) among the different dosing
regimens(meanreductionsfor5,10,20and30 lgdosesof0.47,
0.50,0.69and0.76%[5.1,5.5,7.5and8.3 mmol⁄mol]ononce-
daily administration, respectively, and 0.65, 0.78, 0.75 and
0.87% (7.1, 8.5, 8.2 and 9.5 mmol⁄mol) on twice-daily
administration, respectively), compared with a decrease of
0.18% (2.0 mmol⁄mol) for placebo (Fig. 1). A dose–response
relationship with HbA1c level was seen for both the once daily
and twice daily regimens of lixisenatide, with improvements in
HbA1c observed as early as week 5 (Fig. 1).
Signiﬁcantly more patients in the lixisenatide groups achieved
anHbA1c< 7.0%(53 mmol⁄mol;rangingfrom47to69%with
once daily dosing and from 51 to 77% with twice daily dosing),
compared with 32% of those in the placebo group (P<0.05) at
week 13 (Fig. 2). Further improvement in glycaemic control to
HbA1c < 6.5% (48 mmol⁄mol) at study end was observed in
signiﬁcantly more patients in the lixisenatide groups than in the
placebo group (7.5%); one-third of patients receiving 20 or
30 lg once daily and 5, 10 and 20 lg twice daily achieved this
goal (P<0.0001 for all of these groups vs. placebo and
P = 0.0315 vs. placebo for 5 lg once daily; Fig. 2).
As noted in Table 2, there were dose-dependent reductions
frombaselineinfastingplasmaglucoseandalsoindailyaveraged
seven-point self monitored blood glucose, 2 h post-prandial
plasma glucose concentrations, and in body weight with
lixisenatide.
Safety and tolerability
The most frequent adverse events were gastrointestinal,
primarily dose-dependent nausea (Table 3). The onset of
gastrointestinal adverse reactions was observed during the ﬁrst
5 weeks of the study in the majority of cases, and these were
usually mild-to-moderate in intensity. No cases of pancreatitis
were experienced. There was no evidence of a dose relationship
with symptomatic hypoglycaemic episodes [ranging from 1 to 3
events (0.9–5.7%) per group), which were mostly mild in
intensity. No patients experienced severe hypoglycaemia.
There were zero to three (5.6%) serious adverse events in the
lixisenatide groups and three (2.8%) in the placebo group
(Table 3). These events included one patient in the lixisenatide
30 lg once daily group who discontinued treatment owing to a
few seconds of loss of consciousness and one in the lixisenatide
10 lg once daily group who discontinued secondary to an
allergic reaction (a 30 min episode of pruritus over the entire
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Diabetic Medicine ª 2010 Diabetes UK 1027FIGURE 1 Changesinglycatedhaemoglobin(HbA1c)levelsfollowing13 weeks’treatmentwithlixisenatideoncedailyortwicedaily,accordingtodosageand
regimen. Top panel shows change in mean (sem)H b A 1c over time. Bottom panel shows least square (LS) mean change in HbA1c from baseline to 13 weeks.
FIGURE 2 Percentage of patients with glycated haemoglobin (HbA1c) level of < 7.0% (53 mmol⁄mol; top panel) and < 6.5% (48 mmol⁄mol; bottom
panel) following 13 weeks’ treatment with lixisenatide once daily or twice daily, according to dosage and regimen.
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1028 Diabetic Medicine ª 2010 Diabetes UKbody within 10 min of injecting study drug after 3 weeks of
study treatment, and a second episode 10 min after the next
injection, given 3 days later, with swollen lips⁄tongue and
difﬁculty in breathing that resolved within minutes of receiving
an oral antihistamine). Two non-serious cases of urticaria were
reported with lixisenatide and three with placebo. There was
evidence for a relationship between the lixisenatide dose and
frequency of adverse events (mainly due to gastrointestinal
adverse events), but not with the number of serious adverse
events (Table 3).
The frequencies of patient discontinuations from the study
due to treatment-emergent adverse events ranged from 1.8 to
11.1% in the once daily lixisenatide groups and from 0 to
14.8% in the twice daily lixisenatide groups, while 1.8% of
patients taking placebo discontinued.
No clinically signiﬁcant changes were detected by laboratory
safety assessments and on 12-lead electrocardiogram. Mean
systolic and diastolic blood pressure levels were 130⁄
80 mmHg, respectively, at baseline. A clear trend of systolic
and diastolic blood pressure reductions from baseline to end-
point occurred with each lixisenatide dose (ranging from )2t o
)9 mmHgforthesystolic,and)2to)4 mmHgforthediastolic
blood pressures), and also with placebo ()3 and )2 mmHg for
systolic and diastolic blood pressures, respectively). The
apparent reductions in blood pressure were observed as early
as week 1 in most of the groups and, therefore, appeared to be
independent of reductions in HbA1c and body weight. There
were no relevant changes in heart rate from baseline to
end-point in any of the groups.
The percentages of anti-lixisenatide antibody-positive
subjects at end-point ranged from 43.1% in the 10 lg once
daily group to 71.2% in the 20 lg twice daily group. No
relevant differences were observed in terms of safety and
efﬁcacybetweenthepatientpopulationswithantibody-positive
and negative status at study-end for all dose regimens.
Discussion
In this study, the new GLP-1 receptor agonist lixisenatide
signiﬁcantlyimprovedglycaemiccontrolfromamildlyelevated
meanbaselineHbA1c[7.55%(59.0 mmol⁄mol)]inpatients
with Type 2 diabetes mellitus inadequately controlled with
metformin.
A total of eight regimens, comparing four doses each
administered once or twice daily, were compared with
placebo in order to characterize fully the dose–effect proﬁle of
lixisenatide when added to previous metformin monotherapy.
At week 13, statistically signiﬁcant reductions in the primary
end-point—the HbA1c level—were observed for each dose of
lixisenatide. The efﬁcacy of lixisenatide was dose related across
the once daily dose range with regard to improvements in the
primary and secondary end-points of fasting plasma glucose,
daily averaged seven-point self monitored blood glucose and
2 h post-prandial plasma glucose. Notably, the once daily and
twice daily lixisenatide regimens achieved similar levels of
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Diabetic Medicine ª 2010 Diabetes UK 1029efﬁcacy,anddoublingthedailydose(inthetwicedailyregimens)
did not provide relevant additional improvements in glycaemic
control over the once daily regimens. The efﬁcacy of lixisenatide
appeared to reach a plateau at a dose of 20 lg once daily, with
furtherincreasesofferinglimitedbeneﬁtrelativetotheincreasein
drug exposure. This is in accordance with a pharmacodynamic
studythatfoundthatboth20 lgoncedailyand20 lgtwicedaily
of lixisenatide signiﬁcantly improved HbA1c to a similar extent
vs. placebo, despite the short (4 week) treatment period [13].
There have been a few previous dose-ranging studies of
exenatideorliraglutide[16–19].APhase IIdose-rangingstudyof
exenatide (2.5–10.0 lg) was performed over 4 weeks [18].
Initialdose-rangingstudiesofliraglutidemonotherapyevaluated
doses of 0.045–0.75 mg once daily over 12 weeks [16,17], with
the highest doses giving HbA1c reductions similar to that
observed with lixisenatide 20 lg once daily in the present
study,butfromahigherbaselineHbA1c[16].Asubsequentstudy
appeared to establish a dose–effect plateau at 1.25 and 1.90 mg
once daily in patients with poorer glycaemic control at baseline
[HbA1c 8.1–8.5% (65–69 mmol⁄mol)] [19].
Importantly, over two-thirds of patients on lixisenatide
20 lg once daily and 30 lg once daily reached the target of
HbA1c < 7.0% (53 mmol⁄mol), compared with 32% of
those taking placebo. This suggests that lixisenatide could be
a useful option for helping the large fraction of patients in
clinical practice who do not achieve recommended HbA1c
goals [20], as well as for overcoming the limited therapeutic
response provided by some existing therapies when the
baseline is mildly elevated.
Of note, improvements in glycaemic control with lixisenatide
were coupled with reductions in body weight. This is an
important ﬁnding in light of the high prevalence of obesity and
overweight in this population and the relationship of weight
with insulin resistance and cardiovascular disease [21], as well
as the tendency of current intensive therapy to cause weight gain
[22].
Overall, lixisenatide was well tolerated. Consistent with other
GLP-1 receptor agonists [16,17,23–25], gastrointestinal adverse
events were the most common with lixisenatide, and nausea was
the most frequent of these. Nevertheless, it appears that fewer
patients experienced nausea with the 20 lg once daily dose than
ﬁgures previously reported in clinical studies of twice-daily
exenatide [23–25], but only head-to-head studies can
substantiate this suggestion. The onset of nausea occurred
predominantly during the ﬁrst half of the study and was mild to
moderate in intensity. Only one patient discontinued the study
due to nausea (and none for vomiting) in the 20 lg once daily
lixisenatide group. The risks of hypoglycaemia and serious
adverse events were low and similar across the lixisenatide dose
range. Based on these data, a dose of 20 lg once daily appears
to balance maximal efﬁcacy with good tolerability. However,
the present study has the limitation of a relatively short
treatment period (13 weeks), and the full long-term effect of
lixisenatide on glycaemic control and body weight remains to be
determined.
In conclusion, in this thorough dose-ranging study of four
doses and two regimens, lixisenatide signiﬁcantly improved
glycaemic control in mildly hyperglycaemic patients previously
on metformin monotherapy, with associated weight loss and
withoutcausing signiﬁcanthypoglycaemia.Cleardose–response
relationships and similar levels of efﬁcacy were seen for the once
daily and twice daily regimens, with a 20 lg once daily dose
showing the best efﬁcacy-to-tolerability ratio. This new, once-
daily GLP-1 receptor agonist shows promising efﬁcacy, safety
and tolerability in the management of Type 2 diabetes, but
further investigations in long-term studies are needed.
Table 3 Number (%) of patients with treatment-emergent adverse events occurring in ‡ 10% in any one group and symptomatic hypoglycaemia in the
safety population
Type of adverse event
Placebo
(n = 109)
Lixisenatide
5 lgQ D
(n = 55)
10 lgQ D
(n = 52)
20 lgQ D
(n = 55)
30 lgQ D
(n = 54)
5 lg BID
(n = 53)
10 lg BID
(n = 56)
20 lg BID
(n = 54)
30 lg BID
(n = 54)
Any treatment-emergent
adverse events
65 (59.6) 31 (56.4) 26 (50.0) 37 (67.3) 42 (77.8) 30 (56.6) 32 (57.1) 38 (70.4) 40 (74.1)
Any serious
treatment-emergent
adverse events
3 (2.8) 0 1 (1.9) 1 (1.8) 3 (5.6) 0 1 (1.8) 2 (3.7) 0
Nausea 5 (4.6) 4 (7.3) 6 (11.5) 14 (25.5) 19 (35.2) 4 (7.5) 8 (14.3) 12 (22.2) 18 (33.3)
Vomiting 1 (0.9) 2 (3.6) 3 (5.8) 3 (5.5) 10 (18.5) 3 (5.7) 4 (7.1) 5 (9.3) 2 (3.7)
Diarrhoea 8 (7.3) 3 (5.5) 4 (7.7) 5 (9.1) 4 (7.4) 3 (5.7) 4 (7.1) 6 (11.1) 14 (25.9)
Headache 11 (10.1) 7 (12.7) 3 (5.8) 7 (12.7) 7 (13.0) 7 (13.2) 5 (8.9) 6 (11.1) 4 (7.4)
Dizziness 7 (6.4) 1 (1.8) 4 (7.7) 4 (7.3) 6 (11.1) 3 (5.7) 5 (8.9) 2 (3.7) 5 (9.3)
Symptomatic hypoglycaemia 1 (0.9) 1 (1.8) 2 (3.8) 1 (1.8) 1 (1.9) 3 (5.7) 1 (1.8) 3 (5.6) 1 (1.9)
Data are n (%). Treatment-emergent adverse events were deﬁned as adverse events that developed or worsened during the on-treatment
period (the time from the ﬁrst dose of study medication up to 3 days after the last dose). The safety population was composed of
all randomized patients who took at least one dose of the study medication during the double-blind treatment phase.
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